A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous keratopathy

DOI: 10.1016/j.xcrm.2024.101847

Authors: Masatoshi Hirayama; Shin Hatou; Masaki Nomura; Risa Hokama; Osama Ibrahim Hirayama; Emi Inagaki; Kumi Aso; Tomoko Sayano; Hiromi Dohi; Tadaaki Hanatani; Naoko Takasu; Hideyuki Okano; Kazuno Negishi; Shigeto Shimmura

Step 1: iPSC/ESC maintainance

day 0 ~ 21

culture “adherent” human PSC in “StemFit AK03N” for “21” days. For ECM, use “iMatrix-511MG” at “N/A” “N/A”. Medium should be changed once in “21” days.

Ideally, “PSC” should be obtained at the end of culture.

Step 2: endothelial 1

day 21 ~ 35

culture “adherent” human PSC in “unspecified medium” for “14” days. For ECM, use “iMatrix-511MG” at “N/A” “N/A”. Medium should be changed once in “14” days.

Ideally, “EC” should express “Na,K-ATPase”, “ZO-1”, “N-cadherin”, “PITX2”, “mineralocorticoid receptor”, “ATP1A1”, “CD166”, “CD105”, “CD44”, “CD26”, “CD24” at the end of culture.